Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Dahlia Sano

Assistant professor

Karmanos Cancer Institute

United States

Research Interests

Explore related searches

Professors in United States

Articles (18)

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (5)

Chan Yoon Cheah

University of Western Australia

AUSTRALIA

View details

Yasmin Karimi

University of Michigan

UNITED STATES

View details

Efrat Luttwak

assistant professor

Memorial Sloan Kettering Cancer Center

UNITED STATES

View details

Shannon Carty

University of Michigan

UNITED STATES

View details

Victoria R Nachar

University of Michigan Rogel Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Dahlia Sano

Research Interests

Explore related searches

Articles (18)

Nivolumab in combination with AVD as frontline treatment for patients with classic Hodgkin lymphoma: A real‐world analysis from 20 US centers

Systemic intravascular large B-cell lymphoma relapsing as an extravascular cutaneous large B-cell lymphoma after 8 years from initial diagnosis

Hodgkin Lymphoma, Version 1.2026

Cost effectiveness of mosunetuzumab and CAR-T cell therapy in relapsed/refractory follicular lymphoma.

A real-world analysis of safety and outcomes with first line nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (NAVD) in patients with classic Hodgkin lymphoma (cHL) – a multicenter cohort study

Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma

Nivolumab with doxorubicin, vinblastine, and dacarbazine (NAVD) in older adults with classic Hodgkin lymphoma: Do S1826 results hold up in the real world?

135 | LONG‐TERM FOLLOW UP OF THE VALOR (VENETOCLAX, LENALIDOMIDE, RITUXIMAB) IN PATIENTS W/ UNTREATED MANTLE CELL LYMPHOMA

808 | PHASE 1b/2 STUDY OF MAPLIRPACEPT (PF‐07901801), TAFASITAMAB, AND LENALIDOMIDE IN TRANSPLANT‐INELIGIBLE RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA PARTICIPANTS

Assessment of Tumor Metabolic Volume (TMV) As a Predictor of Outcomes in Patients with Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma (PMBCL)

Outcomes of Sequenced Therapy in Mantle Cell Lymphoma in Patients Treated with First-Line Autologous Stem Cell Transplantation and Second-Line BTK Inhibitor

Risk Factors for Cytokine Release Syndrome in Patients Receiving Bispecific Antibodies for B-Cell Lymphoma: A Single-Center, Retrospective Cohort Study

Risk Factors for Severe Infection in Patients Receiving Bispecific Antibody Therapies for Lymphoma

ABCL-616 Incidence, Characteristics and Outcomes in Relapsed and Refractory CD20+ PTLD: An Institutional Retrospective Cohort Study

Incidence, Characteristics and Outcomes in Relapsed and Refractory CD20+ PTLD: An Institutional Retrospective Cohort Study

Outcomes and prognostic factors of patients diagnosed with relapsed/refractory primary B-cell lymphoma: A retrospective study.

Brentuximab Vedotin Retreatment in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma or Peripheral T-Cell Lymphoma: A Retrospective United States Claims Analysis

Two primary cancers appeared after discontinuation of nivolumab in the course of treating Hodgkin lymphoma: a case report

Collaborators (5)

Chan Yoon Cheah

Yasmin Karimi

Efrat Luttwak

Shannon Carty

Victoria R Nachar

Make your next move.